Presented in AACR 2023
Organoid co-cultures with autologous T cells to assess toxicity and efficacy of bispecific antibodies
![ELRIG 2022 Poster](https://resources.huborganoids.nl/hs-fs/hubfs/Assets%202022/elrig-poster-2022-bispecific-antibodies.png?width=300&name=elrig-poster-2022-bispecific-antibodies.png)
Immunotherapies have demonstrated great success in clinical treatment for certain types of cancer. However, the lack of preclinical models that preserve patient-specific tumor antigen expression and recapitulate the immune cell response to tumors in vivo is hindering the successful development of novel therapeutic strategies.
Download this poster to discover:
- The establishment of a non-small cell lung cancer (NSCLC) organoid and tumor-infiltrating lymphocyte (TIL) co-culture platform
- The available readouts that provide an indication of T-cell bispecific (TCB) activity
- The potential of NSCLC organoid-TIL co-culture platform in assessing the toxicity and efficacy of bispecific antibodies targeting tumor antigens.